Marker Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $6.6M | $3.3M | $3.5M | $0 |
| Operating income | -$12.9M | -$11.1M | -$14.6M | -$19.8M | -$39.5M |
| Operating expenses | $16.4M | $17.7M | $17.9M | $23.3M | $40.7M |
| Cash from operations | -$12.0M | -$10.9M | -$16.4M | -$27.0M | -$27.3M |
| Capital expenditure | — | — | — | $57,607 | $2.2M |
| Free cash flow | — | — | — | -$27.0M | -$29.4M |
| Total assets | $19.1M | $22.0M | $17.1M | $34.4M | $68.1M |
| Total liabilities | $2.3M | $3.5M | $3.1M | $14.8M | $24.1M |
Shares outstanding 16.7M · Free float 50.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.